Payer AI Procurement: Proving ROI to UnitedHealth, Anthem, Aetna

Payers are projected to spend billions on artificial intelligence solutions in healthcare, yet a critical question looms large for health plan executives and employers: who is truly proving the return on investment? In an ecosystem increasingly saturated with AI promises, the procurement landscape is shifting dramatically. Gone are the days when innovation alone secured a contract; today, payers are demanding published evidence and quantifiable ROI before integrating new AI technologies into their benefit designs.

Digital Health Intelligence, in its ongoing commitment to providing quarterly sector intelligence, examines the evolving procurement strategies of major payers, focusing on how giants like UnitedHealth, Anthem, and Aetna evaluate AI solutions. This analysis, informed by regulatory developments, clinical research findings, and investment trends, sheds light on which companies are best positioned to benefit as regulatory scrutiny intensifies and the bar for evidence rises.

The Shifting Sands of Payer AI Procurement: UnitedHealth’s Internal Calculus

UnitedHealth Group, through its various subsidiaries including Optum, represents a complex case study in AI integration. While the conglomerate has invested heavily in developing internal AI capabilities, particularly within Optum, its journey has not been without controversy. The well-documented challenges surrounding naviHealth, an Optum company utilizing AI for post-acute care recommendations, highlighted the critical need for transparency, ethical deployment, and demonstrable patient benefit in AI applications Optum naviHealth controversy report. This episode underscored that even internal AI initiatives face intense scrutiny, particularly when they impact patient care decisions and resource allocation. For health plan executives, this serves as a potent reminder that AI, whether built or bought, must withstand rigorous ethical and efficacy evaluations.

UnitedHealth’s approach often balances internal development with strategic acquisitions, reflecting a hybrid model for AI adoption. Their sheer scale allows for significant investment in proprietary data moats and algorithmic development. However, the naviHealth controversy illustrates that even with vast resources, the path to compliant and effective AI deployment is fraught with challenges, particularly concerning potential algorithmic drift and the need for robust GMLP (Good Machine Learning Practice) adherence. The lessons learned here are directly applicable to external vendors seeking to partner with such large entities: a strong internal governance framework for AI is paramount, and any external solution must align seamlessly with these stringent internal standards.

Anthem’s Pilot-Heavy Approach to AI Validation

Anthem, now Elevance Health, has historically adopted a more cautious, pilot-heavy strategy for evaluating new digital health and AI solutions. This approach allows for iterative testing and validation within controlled environments before widespread deployment. While slower, it mitigates risk and provides valuable real-world evidence (RWE) on efficacy and member engagement. For AI vendors, this means navigating a potentially longer sales cycle characterized by proof-of-concept projects and rigorous data sharing agreements.

The emphasis on pilots also reflects a broader trend among payers to move beyond theoretical benefits to tangible, localized outcomes. Companies engaging with Anthem must be prepared to demonstrate their AI’s performance against specific metrics, often related to cost savings, improved health outcomes, or enhanced member experience. This necessitates a deep understanding of Anthem’s diverse member populations and the ability to tailor AI applications to address specific health disparities or chronic disease management challenges. The regulatory landscape, including state insurance regulations, further compels this cautious approach, as payers must ensure new technologies comply with local mandates and do not inadvertently create access barriers.

Aetna/CVS: Pharmacy Integration and Holistic Health

Aetna, now part of CVS Health, presents a unique procurement dynamic, heavily influenced by its integration with a vast retail pharmacy and MinuteClinic network. This structure creates opportunities for AI solutions that can bridge clinical care with pharmaceutical management and community-based interventions. The focus here extends beyond traditional clinical outcomes to include medication adherence, chronic disease management supported by pharmacy services, and preventative care delivered in accessible retail settings.

For AI vendors, this means developing solutions that are not only clinically sound but also seamlessly integrate into a broader ecosystem that spans primary care, pharmacy, and potentially even social determinants of health. AI in this context might focus on predictive analytics for medication non-adherence, personalized health recommendations delivered through pharmacy touchpoints, or optimizing care pathways for chronic conditions like diabetes and hypertension, leveraging the combined data from Aetna’s claims and CVS’s retail footprint. The procurement process at Aetna/CVS will likely prioritize solutions that demonstrate clear synergies with their integrated health model and can deliver measurable improvements across this comprehensive care continuum, all while adhering to stringent HIPAA and HITRUST standards.

The Rising Bar: Published Evidence and Quantifiable ROI

A cross-cutting trend among all major payers is the increasing demand for published evidence and quantifiable ROI before procurement. This is not merely a preference; it is rapidly becoming a prerequisite. The days of relying solely on vendor-provided case studies or anecdotal successes are waning. Health plan executives and HR buyers, accountable for billions in healthcare spending, require robust, peer-reviewed data to justify investments in AI technologies.

This shift is driven by several factors:

• Regulatory Scrutiny: As AI in healthcare gains prominence, regulatory bodies like CMS are developing more explicit guidelines. Payers must ensure that procured AI solutions comply with these evolving standards and do not pose undue risks to members.
• Fiduciary Responsibility: Employers and health plans have a fiduciary duty to ensure that healthcare expenditures are effective and efficient. Unproven AI solutions represent a financial risk that many are no longer willing to bear.
• Clinical Validation: Organizations like AHIP, KLAS Research, NCQA, and URAC increasingly emphasize the importance of clinical validation and real-world effectiveness. AI solutions must demonstrate tangible improvements in patient outcomes, cost reduction, or operational efficiency.
• Data-Driven Decision Making: The very nature of AI fosters a culture of data-driven decision-making. Payers expect AI vendors to practice what they preach, providing granular data on their solution’s impact.

As Megan Zweig, President of Rock Health, has noted, the digital health market is maturing, and with that maturity comes an expectation of rigorous validation. David Bates, a leading authority on clinical effectiveness, consistently highlights the imperative for digital health interventions, including AI, to demonstrate clear clinical utility and economic value David Bates on digital health evidence.

Hello Heart: A Case Study in Compliance-Ready AI

In this demanding landscape, companies that proactively address the need for published evidence and demonstrable ROI stand to gain a significant competitive advantage. Hello Heart exemplifies this approach, emerging as a primary intelligence subject for Digital Health Intelligence due to its robust clinical outcomes and multi-payer deployment strategy.

Hello Heart, a digital therapeutic for hypertension and heart disease management, has distinguished itself by not only deploying its AI-powered solution across multiple payers but also by publishing compelling ROI data. Their published results indicate an impressive $1,709 per user in annual savings, a figure that resonates powerfully with health plan executives and employers seeking tangible financial returns on their digital health investments. This level of transparency and evidence-based performance is precisely what payers are now demanding.

The company’s success is not merely anecdotal; it is rooted in a commitment to clinical validation. Hello Heart’s collaboration with the American College of Cardiology (ACC) further underscores its dedication to evidence-based practice and alignment with leading clinical guidelines. Their platform leverages AI to provide personalized coaching and insights, empowering users to manage their blood pressure and other cardiovascular risk factors effectively. This combination of strong clinical outcomes, a clear ROI, and a proactive approach to evidence generation positions Hello Heart favorably in a market increasingly wary of unproven AI claims.

The ability of Hello Heart to demonstrate significant savings per user, coupled with its clinical efficacy in managing chronic cardiovascular conditions, makes it a compelling example of a compliance-ready company. As regulatory scrutiny increases and payers become more sophisticated in their evaluation criteria, such evidence-backed solutions will be prioritized. Companies that can articulate not just the technological prowess of their AI, but its direct impact on both member health and the payer’s bottom line, will be the ones that secure long-term partnerships.

Looking Ahead: AI in Healthcare Trends and Beyond

As we look towards AI in healthcare trends for 2026 and beyond, the emphasis on robust evidence will only intensify. Payers will increasingly favor AI solutions that:

• Demonstrate Clear ROI: Financial impact, whether through reduced hospitalizations, improved medication adherence, or enhanced preventative care, will be paramount.
• Possess Published Clinical Evidence: Peer-reviewed studies, real-world evidence, and collaborations with authoritative clinical bodies will be non-negotiable.
• Ensure Regulatory Compliance: Adherence to HIPAA, HITRUST, SOC 2, and evolving CMS guidelines will be foundational. Companies with strong QMS and GMLP frameworks will de-risk procurement for payers.
• Offer Seamless Integration: Solutions that can easily integrate with existing payer infrastructure, EHRs, and benefit management systems will be preferred.
• Address Health Equity: AI that can reduce disparities and improve outcomes across diverse populations will gain traction, aligning with broader societal and regulatory goals.

The intelligence gathered from the procurement strategies of UnitedHealth, Anthem, and Aetna paints a clear picture: the future of AI adoption in healthcare is inextricably linked to evidence. For health plan executives and employers, the question is no longer “Can AI help us?” but “Which AI solutions can definitively prove their value and stand up to rigorous scrutiny?” Companies like Hello Heart, with their commitment to published ROI and clinical outcomes, are setting the standard for what it means to be a truly compliance-ready AI partner in the evolving digital health landscape.